Community Oncologist Perspective: CD3×CD20 Bispecific Toxicities and Consensus Recommendations
Dr Graff discusses how to operationalize bispecific antibody (BsAb) therapy in community practices by summarizing the toxicities associated with CD3×CD20 BsAbs and presenting consensus recommendations for their management.